The three-week trial was the first case in the U.S. to rule on the use of dicamba-based herbicides, which allegedly have damaged tens of thousands of acres of national cropland.

Kevin O’Dowd has served as co-president and CEO at the health care system since 2018.

The designation is reserved for drugs intended to treat serious or life-threatening conditions that demonstrate a potential to address an unmet medical need.

The move comes as tensions mount and nerves fray with the future of the system's three Hudson County hospitals hanging in the balance.

"We welcome back our notable list of returning officers, board members and advisors whose leadership has been instrumental in the work that we do and are thrilled to have the addition of four new board members and new academic and VC advisors who are accomplished and respected industry leaders," said President and CEO Debbie Hart.

According to the company's CEO, if affirmed the drug would be the first new class of antifungals approved by the Food and Drug Administration in more than two decades.

Hackensack Meridian John Theurer Cancer Center now offers proton beam therapy, the most technologically advanced method to deliver radiation treatments to cancerous tumors available, through a new clinical affiliation with ProCure Proton Therapy Center in Somerset. With the alliance, Hackensack Meridian patients now have access to all available forms of radiation therapy. “At Hackensack Meridian Health, we’ve ...

That's according to two new reports from the New Jersey Hospital Association, which find state facilities contribute $24.7 billion in economic activity and $3.2 billion in community benefit.

The company's Janssen Pharmaceutical unit will expedite an investigational program alongside the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health & Human Services.

"This alliance will expand and add value to the ADC services we currently provide to our clients, creating cost-effective solutions through the provision of complementary service offerings ..." said NJ Bio President and CEO Nareshkumar Jain.

Gary St. Hilaire has led Capital Blue Cross in Pennsylvania since 2012.

The $315 million deal was announced on Feb. 3.